- Home
- PROK vs TTGT Comparison
PROK vs TTGT Comparison
Compare PROK & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | TTGT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 344.2M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PROK | TTGT |
|---|---|---|
| Price | $1.93 | $4.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $7.40 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.1M | 305.0K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | $4.45 |
| Revenue Next Year | N/A | $2.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $3.41 |
| 52 Week High | $7.13 | $9.00 |
Technical Indicators
Market Signals| Indicator | PROK | TTGT |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 54.79 |
| Support Level | $1.71 | $3.49 |
| Resistance Level | $2.58 | $4.75 |
| Average True Range (ATR) | 0.14 | 0.32 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 78.95 | 62.20 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.